期刊文献+

骨髓间质干细胞输注对庆大霉素致急性肾小管损伤细胞增殖和凋亡的影响 被引量:1

Effects of infusion of bone marrow mesenchymal stem cells on proliferation and apoptosis in gentamicin-induced acute renal failure in rat
下载PDF
导出
摘要 目的观察骨髓间质干细胞(MSCs)对庆大霉素导致的急性肾功能衰竭(ARF)的疗效,并探讨其可能的机制。方法建立庆大霉素皮下注射致大鼠ARF模型。雄性SD大鼠MSCs用4,6-二乙酰基-2-苯基吲哚(DAPI)标记。雌性SD大鼠随机分为对照组(C组)、MSCs组(M组)和DMEM-F12组(D组)。C组未给予任何处理;M组在每次给予庆大霉素的同时经尾静脉静注DAPI标记的MSCs;D组在每次给予庆大霉素的同时注入无血清DMEM-F12。7d后观察血尿素氮(BUN)和血肌酐(Scr)以及肾脏病理改变(HSK评分),采用原位末端标记法检测细胞凋亡指数(AI),免疫组化法检测增殖细胞核抗原(PCNA)、Bcl-2、Fas/FasL的表达,并观察DAPI标记的MSCs在受体大鼠肾脏的分布情况。结果M组的HSK评分、BUN、Scr(分别为5.5±0.8、11.6±2.2mmol/L、93.5±13.1μmol/L)均低于D组(分别为10.2±0.8、22.2±6.3mmol/L、204.4±53.1μmol/L,P<0.05);M组肾小管上皮细胞PCNA+细胞数、AI(分别为20.8%±3.7%、15.73%±2.43%)低于D组(分别为42.1%±5.2%、23.76%±4.30%,P<0.05)。M组Bcl-2表达(35.27%±2.93%)高于D组(25.28%±3.10%,P<0.05);M组Fas、FasL(分别为21.53%±3.72%、20.50%±3.71%)均低于D组(37.28%±11.14%、37.66%±10.59%,P<0.05)。整个实验期间未发现MSCs定位于肾组织中。结论外源性MSCs可以促进ARF损伤后肾小管上皮细胞的增殖并减少细胞凋亡,促进Bcl-2和抑制Fas/FasL表达,从而有利于肾小管损伤的早期恢复。 Objective To investigate the effects of mesenchymal stem cells (MSCs) on the recovery of gentamicin-induced acute re hal failure (ARF), and explore its possible mechanism. Methods MSCs were isolated from a male SD rat and labeled with DAPI before in jection. ARF rat model was reproduced by hypodermic injection of gentamicin. At the time that gentarncin was injected, MSCs were injected through tail vein. Thirty SD rats were randomly divided into three groups (10 each): MSCs injection group (group M), DMEM-F12 infusion group (group D) and control group (group C). Rats were sacrificed on day 7 after gantamiein injection. The levels of serum Scr and BUN were determined, and the renal tissue was sampled for pathological observation. Cell apoptotic index (AI) was calculated after terminal deoxynucleotidyl transferase mediated d-UTP nick end labeling (TUNEL). The expressions of Bcl-2, Fas and FasL proteins and PCNA were determined by immunohistochemical technique. The distribution of DAPI positive MSCs in kidney of recipient SD rats was examined by immunohistochemistry. Results HSK score (5.5±0.8 vs 10.2±0.8, P〈0.05), BUN (11.6±2.2 mmol/L vs22.2±6.3mmol/L, P〈0. 05) and Scr (93.5±13. 1μmol/L vs 204.4±53.1μmol/L, P〈0.05) were lower in group M than those in group D. PCNA positive cells (20. 8%±3. 7% ws 42. 1%±5. 2%, P〈0. 05) and AI (15. 73%±2. 43% vs 23. 76%±4. 30%, P〈0. 05) in group M were lower than those in group D. The expressions of Bcl-2 in group M were higher than those in group D (35.27% ± 2.93% vs 25. 28%±3. 10%, P〈0. 05), and the expressions of Fas (21.53±3. 72% vs 37. 28%±11.14%, P〈0. 05), FasL (20. 50±3.71% vs 37. 66%±10. 59%, P〈0.05) were lower in group M than those in group D. MSCs were not trapped in renal tissue of MSC-treated rats. Conclusions MSCs can accelerate proliferation and decrease apoptosis of renal tubular epithelial cells after ARF, promote the expression of Bcl-2 and restrain the expressions of Fas and FasL, and improve the recovery of gentamicin-induced acute renal tubular epithelial ceils damage.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2008年第9期1085-1088,共4页 Medical Journal of Chinese People's Liberation Army
基金 陕西省科技攻关基金项目[2006K13-G5(5)]
关键词 再灌注损伤 间质于细胞 细胞凋亡 基因 reperfusion injury kidney mesenchymal stem cells apoptosis genes
  • 相关文献

参考文献12

  • 1Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemie acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol, 2005, 289(1) : F31
  • 2Krause D, Cantley LG. Bone marrow plasticity revisited:protection or differentiation in the kidney tubule? J Clin Invest, 2005, 115(7):1705.
  • 3Lin F. Stem Cells in Kidney Regeneration Following Acute Renal Injury. Pediatr Res, 2006, 59 (4 Pt 2): 74R
  • 4Sekiya I, Larson BL, Smith JR, et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 2002, 20(6) : 530
  • 5Xie Y, Nishi S, Iguehi S, et al. Expression of osteopontin in gentamicin-induced acute tubular necrosis and its recovery process. Kidney Int. 2001, 59(3) :959
  • 6Blydt-Hansen TD, Katori M, Lassman C, et al. Gene transfer-induced local heine oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol. 2003, 14(3) : 745
  • 7Orlic D. Stem cell repair in ischemic heart disease: an experimental model. Hematol, 2002, 76(Suppl 1): 144
  • 8Lin F, Moran A, Igarashi P. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postisehemic kidney. J Clin Invest, 2005, 115(7):17,56
  • 9Nogae S, MiyazakiM, KohayashiN, et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol, 1998, 9(4): 620
  • 10Devarajan P, Mishra J, Supavekin S, et al. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Gene Metab, 2003, 80(4):365

同被引文献34

  • 1Yanez-Mo M, Lara-Pezzi E, Selgas R, et al. Peritoneal dialysis and epithelial-to-mesenehymal transition of mesothelial cells[J]. N Engl J Med, 2003, 348(5): 403-413.
  • 2Lopez-Cabrera M, Aguilera A, Aroeira LS, et al. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure[J]. Perit Dial Int, 2006, 26(1): 26-34.
  • 3Loureiro J, Sehilte M, Aguilera A, et al. BMP-7 blocks mesenchymal conversion of memthelial cells and prevents peritoneal damage induced by dialysis fluid exposure[J]. Nephrol Dial Transplant, 2010, 25(4) : 1098-1108.
  • 4Hekking LH, Harvey VS, Havenith CE, et al. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis[J]. Perk Dial Int, 2003, 23(4): 323-330.
  • 5Kanazawa H, Fujimoto Y, Teratani T, et al. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model[J]. PLoS One, 2011, 6(4): e19195.
  • 6Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchyreal stem cells improves cardiac function in a rat model of dilated cardiomyopathy[J]. Circulation, 2005, 112(8); 1128-1135.
  • 7Ortiz LA, Gambelli F, McBride C, etal. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotie effects[J]. Proc Natl Acad Sci USA, 2003, 100(14) : 8407-8411.
  • 8Oyagi S, Hirose M, Kojima M, et at. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats[J].J Hepatol, 2006, 44(4) : 742-748.
  • 9Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3 deficient mice[J]. Kidney Int, 2006, 70(1): 121-129.
  • 10Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics [J]. Annu Rev Biomed Eng, 2010, 12: 87-117.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部